Report of the Directors
Business Review

Delivering Value

Supporting Our Strategy in Fine Chemicals

People around the world are living longer. As a result, many will suffer from chronic diseases and will require more long term drug therapy. This, together with increasing demand from doctors and patients for efficient pain management and continued economic development in Asia, will further drive demand for pharmaceutical products.

Johnson Matthey holds a strong position in opiate based active pharmaceutical ingredients (APIs), which are used to relieve pain, and in other niche controlled APIs, in particular amphetamines used in the treatment of attention deficit hyperactivity disorder (ADHD). Its API Manufacturing businesses, based in the UK and USA, delivered strong growth this year, increasing their sales and growing market share.

This performance was supported by the businesses’ Riverside manufacturing facility, located in Conshohocken, USA, which was acquired by Johnson Matthey in November 2010. This new plant, which more than doubles our manufacturing capacity in North America, has been successfully integrated with the businesses’ other operations and is enabling us to manufacture products more efficiently, support growth and capitalise on new market opportunities.

Governance.
Back to top

© 2012 Johnson Matthey Plc. Disclaimer and Copyright Notice. We use cookies to help understand how people use our website.
By using our site, you agree to our use of cookies. Find out more in our privacy policy.